Immunotherapy can reverse tumor immune escape by suppressing immune checkpoints, and immune checkpoint blockade with antibodies against programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) has shown promise as an immunotherapy treatment strategy for NSCLC patients (3–5). Here, CD274 is linked to neoplasm.